Psychogenic paroxysmal movement disorders – Clinical features and diagnostic clues  by Ganos, Christos et al.
lable at ScienceDirect
Parkinsonism and Related Disorders 20 (2014) 41e46Contents lists avaiEditor’s comment: The paroxysmal movement disorders are a group of etiologically and clinically heterogeneous conditions, that include
secondary (symptomatic), primary (genetic), and psychogenic forms. In the absence of biomarkers or supportive ancillary examinations,
the diagnosis of a psychogenic movement disorder remains based on clinical grounds, and it should only be made after the secondary
and genetic forms are carefully excluded. In this context, the recent availability of genetic diagnostic tools for the three main categories
of primary paroxysmal dyskinesias (PRRT2, MR-1, and GLUT-1 gene mutations cause kinesigenic, non-kinesigenic, and exercise-induced
dyskinesias, respectively) has renewed interest into the phenomenology and the differential diagnosis of the different genetic as well
as the psychogenic forms. In this issue of the journal, Ganos and colleagues describe a considerable number of patients diagnosed with
psychogenic paroxysmal movement disorders, and compare their clinical features with those of patients with different, genetically proven,
primary forms. Keeping in mind some limitations, mainly concerning the retrospective nature of the case-ascertainment, and the compar-
isons made with previously published genetic series, this novel study offers a number of clinical clues that might help the neurologists in
making a correct diagnosis of psychogenic paroxysmal movement disorder. This exercise has practical implications, because a correct diag-
nosis leads to therapeutic approaches that are efﬁcacious in many of these patients.
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Background: The diagnosis of psychogenic paroxysmal movement disorders (PPMD) can be challenging,
in particular their distinction from the primary paroxysmal dyskinesias (PxD) remains difﬁcult.
Methods: Here we present a large series of 26 PPMD cases, describe their characteristics, contrast them
with primary PxD and focus on their distinguishing diagnostic features.
Results: Mean age at onset was 38.6 years, i.e. much later than primary PxD. Womenwere predominantly
affected (73%). Most subjects (88.4%) had long attacks, and unlike primary PxD there was a very high
within-subject variability for attack phenomenology, duration and frequency. Dystonia was the most
common single movement disorder presentation, but 69.2% of the patients had mixed or complex PxD. In
50% of PPMD cases attack triggers could be identiﬁed but these were unusual for primary PxD. 42.3% of
patients employed unusual strategies to alleviate or stop the attacks. Response to typical medication
used for primary PxD was poor. Precipitation of the disorder due to physical or emotional life events and
stressors were documented in 57.6% and 65.3% of the cases respectively. Additional interictal psychogenic
signs were documented in 34.6% and further medically unexplained somatic symptoms were present in
50% of the cases. 19.2% of patients had a comorbid organic movement disorder and 26.9% had pre-
existing psychiatric comorbidities./724229; fax: þ44 (0)207 676 2062.
).
r Ltd. Open access under CC BY license.
C. Ganos et al. / Parkinsonism and Related Disorders 20 (2014) 41e4642Conclusion: Although the phenotypic presentation of PPMD can be highly diverse, certain clinical
characteristics help in distinguishing this condition from the primary forms of PxD. Recognition is
important as multidisciplinary treatment approaches led to signiﬁcant improvement in most cases.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.Table 1
Patient characteristics.
Number of cases 26
Criteria for diagnosis of PMDa 7 Documented/19
clinically established
Mean age at onset of symptoms (SD) 38.6 (15.6)
Gender (male/female) 7/19
Type of paroxysmal movement disorder 4 Dystonia/2 tremor/2
jerks/7 mixed/11 complex
Attack duration (<5 min/>5 min) 3/23
Presence of triggers 13 (50%)
Presence of relieving factors/manoeuvres 11 (42.3%)
Presence of unexplained somatic symptoms 13 (50%)
Family history for neurological disorders 7 (26.9%)
Concomitant organic movement disorders 5 (19.2%)
SD ¼ standard deviation, PMD ¼ psychogenic movement disorder.
a Diagnosis according to the Fahn and Williams criteria [21].1. Introduction
The spectrum of paroxysmal dyskinesias (PxD) encompasses
different conditions characterized by sudden episodes of involun-
tary movements (e.g. dystonic, choreatic, ballistic) lasting for brief
(but variable) periods of time and triggered by different factors [1].
They are divided into primary, which can be familial or sporadic
and where routine clinical examinations are unrevealing, and sec-
ondary, where structural lesions are typically identiﬁed linked to
the onset and phenomenology of the presenting symptoms [1].
Depending on the type of PxD, treatment and prognosis vary.
Familial clustering of primary PxD has been recognised since
their original description [2] and clinical cohort and genetic studies
have led to their aetiological delineation and clear genotypee
phenotype correlations. Thus, the clinical characteristics of the
three major primary PxD, i.e. paroxysmal kinesigenic dyskinesia,
(PKD), paroxysmal non-kinesigenic dyskinesia (PNKD) and parox-
ysmal exercise-induced dyskinesia (PED) due to respective muta-
tions in the Proline-rich transmembrane protein 2 (PRRT2),
Myoﬁbrillogenesis regulator 1(MR-1) and Glucose transporter 1
(GLUT-1) genes are now very well described [3e16]. This helps to
guide treatment selection and diagnostic differentiation of other
causes of paroxysmal movement disorders.
Numerous causes for secondary PxD have been reported [17e
19]. However, psychogenic (or functional) PxD have received
limited attention in recent literature [20e24], in particular after the
genetic delineation of the primary forms. In view of the sparse
information on the phenomenology of psychogenic paroxysmal
movement disorders (PPMD) and treatment options [20e24], we
sought to explore their explicit clinical characteristics and aimed to
identify clinical features which help distinguishing them from
primary PxD. Therefore, herewe present a large series of 26 cases of
PPMD illustrating their diverse phenomenology, associated fea-
tures and clinical course. We compare them to the classic pheno-
typic characteristics of primary PxD and propose a list of red ﬂags
that can aid clinicians in the diagnosis of PPMD.
2. Patients and methods
We retrospectively reviewed medical records of patients who were diagnosed
with psychogenic movement disorders (PMD) between 2006 and 2013 in the
movement disorders clinic of the National Hospital for Neurology and Neurosurgery,
Queen Square, London.
All cases were seen either by K.B. or M.J.E. or both. Diagnosis of PMD was made
based on the criteria proposed by Fahn and Williams [21] and only cases with
documented or clinically established PMD were included. We selected those cases
where paroxysmal attacks of abnormal movement were the main clinical presenta-
tion. In addition, cases where “altered consciousness” was the predominant feature
bearing resemblance to non-epileptic attacks were excluded from further analysis.
Investigations relevant to the clinical presentation, including brain and/or spinal
imaging (24 cases), electroencephalography (EEG) and/or video-EEG (17 and six
cases respectively), biochemical investigations (e.g. cerebrospinal ﬂuid, serum
copper and ceruloplasmin levels in ﬁve cases) were performed as part of the diag-
nostic work-up.
Supplementary video related to this article can be found online at http://dx.doi.
org/10.1016/j.parkreldis.2013.09.012.
We speciﬁcally collected information on age at onset, attack phenomenology,
attack duration and frequency, as well as speciﬁc triggers of attacks. We also
examined the presence of precipitating factors preceding the ﬁrst attack, environ-
mental stressors, the proﬁle of comorbidities and family history for neurological
disorders. Where possible, we also examined the clinical course of the disorder and
its response to treatment. This study was performed with permission of the local
ethics committee.3. Results
Within the selected timeframe 245 PMD cases were identiﬁed.
Twenty-six (10.6%) presented with a PPMD (individual patient
characteristics are given in supplementary Table 1). According to
published diagnostic criteria [21], a documented PMD was diag-
nosed in seven patients, whereas the remaining 19 were catego-
rized as clinically established. Clinical characteristics of all patients
are summarized in Table 1.
Mean age at onset was 38.6 years (range 16e82 years; SD 15.6
years). Nineteen (73%) patients were female (F:M ¼ 2.7:1). Eight
patients (30.7%) had one type of movement disorder during epi-
sodes, with dystonia being the most common (n ¼ 4; 15.3%). Iso-
lated paroxysmal tremor or jerks were each seen in two patients
(7.6%). Seven patients (26.9%) had a combination of two movement
disorders, typically dystonia and tremor. Eleven patients (42.3%)
had complex generalised movements, challenging established
movement disorders classiﬁcations of hyperkinesias. Attacks
commonly occurred bilaterally (n ¼ 12) when they mainly affected
the arms and legs. Only four patients presented with unilateral
attacks (cases 3, 6, 15, 26). The head/face or trunk were predomi-
nantly affected in seven and six cases respectively. In seven cases
(26.9%) the phenomenological characteristics between attacks
varied (video segments E1-3).
Six cases also had speech disturbances during attacks (23%;
cases 3, 5, 7, 9, 11, 21), four reported pain (15.3%; cases 11, 15, 19, 26)
and ﬁve additional somatic complains such as breathlessness, rapid
breathing, light-headedness, drowsiness, fatigue, chest tightness or
blurring vision (19.2%; cases 2, 3, 5, 6, 20).
In addition to movement disorders, three patients (cases 7, 19,
25) had rare occasions of unresponsiveness during attacks. Another
four cases had episodes of “collapse” but without loss of con-
sciousness in addition to their usual paroxysmal phenomena (cases
9, 11, 13, 14).
Five patients (19.2%) had a coexistent organic movement dis-
order consisting of simple motor tics (n ¼ 2), cervical dystonia
(n ¼ 1), writer’s cramp (n ¼ 1) and mild unilateral postural tremor
secondary to brain surgery at the age of 3 (right thalamic glioma)
(n¼ 1). Six patients (23%) were diagnosed with depression and two
(7.6%) with an anxiety disorder after formal psychiatric assessment.
None of the presented cases had a positive family history of primary
PxD. However in one patient (case 25) there were two family
Table 2
Main Clinical features of primary paroxysmal dyskinesias and psychogenic paroxysmal movement disorders.
Condition PKD PNKD PED PPMD
Age onset (years) 1e20 Infancy or early childhood Usually childhood to early adulthood Adulthood
Triggers Kinesigenic (sudden movement,
usually whole-body)
Caffeine, alcohol, stress,
excitement,
Physical exertion Diverse
Duration <1 mina 10 mine1 ha 15 min (<1 mine3 h) Highly variable
(secondsehours or days)
Frequency Daily Variable, usually 1/week Usually weekly Highly variable, usually daily
Gene PRRT2 MR-1 GLUT-1 e
Phenomenology Dystonia, chorea, balism or mixed
movement disorder.
Uni-/bilateral or alternating
Dystonia, chorea or both. Choreoathetosis, dystonia or both.
Legs invariably affected. Lateralization
common.
Dystonia, tremor, jerks. Mixed
presentation common.
Predominant involvement
of limbs bilaterally, followed by
head/face and trunk
Level of responsiveness Normal Normal Normal Unresponsiveness possible
Pain No Possible Usually none Possible
Response to medication Excellent to carbamazepine,
phenytoin
Some comfort with
benzodiazepines
Good response to ketogenic diet Usually none. Some beneﬁt
from benzodiazepines, or dramatic
response to placebo.
Associated features ICCA, hemiplegic migraine,
Episodic ataxia
Migraine headache Epilepsy, mental retardation, ataxia Somatisations, unusual
precipitants and stressors
Family history Most likely Yes Possible No
Reference [4,8,10] [5] [12] Current study
PKD¼ Paroxysmal kinesigenic dyskinesia, PNKD ¼ Paroxysmal non-kinesigenic dyskinesia, PED ¼ Paroxysmal exercise-induced dyskinesia, PPMD¼ Psychogenic paroxysmal
movement disorder, PRRT2 ¼ Proline-rich transmembrane protein 2, MR-1 ¼ Myoﬁbrillogenesis regulator 1, GLUT-1 ¼ Glucose transporter 1, ICCA ¼ Infantile convulsions
with choreoathetosis.
a Rare cases with longer duration possible.
C. Ganos et al. / Parkinsonism and Related Disorders 20 (2014) 41e46 43members with episodes of hyperglycaemic periodic paralysis.
Further 6 patients had a positive family history for neurological
disorders (supplementary Table 1).
Psychogenic physical signs on interictal examination were
documented in nine (34.6%) patients. They included gait difﬁculties
(n ¼ 7, cases 1, 4, 6, 11, 14, 15, 23; 23%), give way weakness (n ¼ 4,
cases 6, 7, 9,11; 15.3%), non-anatomical sensory disturbances (n¼ 3,
cases 6, 7, 11; 11.5%) and ﬁxed dystonic postures of the feet (n ¼ 2,
cases 7,14; 7.6%). These patients were included because paroxysmal
symptoms were the presenting and most prominent clinical char-
acteristic in them.
Medically unexplained somatic symptoms such as diffuse
abdominal symptoms, chest pain, palpitations, swallowing difﬁ-
culties, voice changes, dizziness and headaches were found in 13
patients (50%).
Only three patients reported short attacks (<5 min) (cases 18,
20, 23). Largewithin- and between-patient duration variability was
found in all other cases. This ranged between a few minutes to
several hours or even days (supplementary Table 1). In case 15,
attack duration ranged from a few hours to 1 week. Attack fre-
quency between patients ranged from several times a day to once
every three months (supplementary Table 1).
Speciﬁc attack triggers were documented in 13 cases (50%).
These involved “increased stress” in three patients, alcohol intake
in two cases, as well as walking, loud noises, feeling frightened or
thirsty in individual cases (supplementary Table 1). In one patient
(case 25, video segment B) attacks were triggered by sounds of pre-
recorded incantations. Nine patients (34.6%) experienced attacks of
their paroxysmal movement disorder during examination.
Precipitants prior to the onset of the movement disorder could
be identiﬁed in 15 cases (57.6%). These included accidental in-
juries, recent illness, invasive medical procedures and antibiotic
intake, physical assault, giving birth, family problems, as well as
changing religious beliefs (supplementary Table 1). Stressors
augmenting the disorder’s manifestation were found in 17 (65.3%)
cases. Common stressors were family or work problems, health-
related issues of the affected individual or of close familial mem-
bers. Alleviating factors were recognized in 11 (42.3%) cases and
included treatment with diazepam (n ¼ 4, cases 4, 5, 7, 26),gabapentin intake with immediate (placebo) therapeutic response
(n ¼ 1, case 11), pressure on the affected body part (n ¼ 3, cases 9,
23,26), focussing attention to an external object (e.g. on examiners
button hole, n ¼ 1, case 21, video segment C), focussing attention
to affected body parts and moving the non-affected contralateral
limbs (n ¼ 1, case 16), trigger avoidance (n ¼ 1, case 25), as well as
reducing physical exercise (n ¼ 1, case 12) or sleep (n ¼ 1, case 26)
(supplementary Table 1).
The most commonly commenced medication prior to diagnosis
of a PPMD was antiepileptics (n ¼ 7), which with the exception of
one case with placebo response (case 11, see above), had been
ineffective. Benzodiazepines (n ¼ 8) had relieved symptoms in
four cases. Baclofen (n ¼ 1), trihexyphenidyl (n ¼ 1), levodopa
(n ¼ 1), as well as risperidone and tetrabenazine (n ¼ 1) had also
been tried also unsuccessfully. Seven patients were receiving
antidepressants.
Seventeen patients (65.3%) experienced signiﬁcant disability
due to their movement disorder, having to leave their work or
college with restriction of their daily activities. Six patients (23%)
had impaired mobility and used stick or wheelchair between at-
tacks. In one case, where symptoms emerged after a car accident
with a whiplash injury, there was an ongoing litigation process.
Follow-up information was available for 17 cases. The diagnosis
was carefully explained to and accepted by all patients but three,
who remained symptomatic at follow-up (mean follow-up period
2.3 years). In one of them (case 17) a litigation process was ongoing.
Five patients showed spontaneous symptom amelioration upon
diagnosis. Five patients agreed to participate in a multidisciplinary
neuropsychiatric rehabilitation program with signiﬁcant improve-
ment. Three patients (cases 1, 8, 16) beneﬁted from local injections
with botulinum toxin, two (cases 1, 8) had an immediate (placebo)
response. One patient (case 22) improved upon restarting
employment. One patient reported symptom relief on commencing
acetazolamide.
4. Discussion
Here we present the phenotypic characteristics of a large series
of 26 cases of PPMD reviewed in our centre. They accounted for
C. Ganos et al. / Parkinsonism and Related Disorders 20 (2014) 41e464410.6% of PMD during the assessed timeframe. Although there has
been limited focus on PPMD in recent medical literature [20e24],
their distinction from the three classic primary PxD (i.e. PKD, PNKD
and PED) (Table 2) is of great importance, since management dif-
fers. Based on the presented data we have identiﬁed a number of
characteristics, which may aid clinicians in differentiation of PPMD
from the primary PxD leading to appropriate treatment.
4.1. Age of onset
The average age of symptom onset was 38.6 years in our re-
ported cases, in contrast to previous reports of PKD, PNKD and PED,
which classically manifest at much earlier ages (Table 2). Although,
unusual cases of classic PKD and PNKD have been published with
patients developing symptoms at a later age (27 and 21 respec-
tively) [4,5] and PPMD have been described in children [25], this is
very rare. Therefore, as previously noted [26], we also suggest that
an adult age at onset (particularly above the age of 25 years) should
be considered as a diagnostic clue pointing towards a secondary or
psychogenic cause of PxD.
4.2. Phenomenology of attacks
The single most common phenotypic presentation in our cases
was that of dystonia, mirroring previous data [21], followed by
tremor and jerks. However, most cases presented with a combi-
nation of at least two paroxysmal movement disorders and 11 cases
presented with more complex movement disorders difﬁcult to
classify. In all cases the phenomenological presentation was
incongruent with primary PxD (Table 2), but also variable in 26.9%
of individuals (video E1-3). Moreover, the presence of paroxysmal
tremor (demonstrated as the sole phenomenon in video segment
E3, and adjoined with further movement disorders in video seg-
ments C and D) has never been reported in primary PxD, and is a
useful additional diagnostic clue for PPMD (Table 3).
In addition, clinical inconsistencies, such as induction of an
attack or increase in severity during examination, as well as
distractibility, entrainment, placebo response to medication, but
also other psychogenic physical signs were found in the majority of
patients. These features are inconsistent and incongruent to the
phenotypic presentation of primary PxD, which by virtue of the
Williams and Fahn [21] criteria for PMD constitute important clues
towards the diagnosis of PPMD (Table 2).
19.2% of the presented cases had a coexistent organic movement
disorder, which reﬂects reported estimates of patients with
concomitant psychogenic and organic movement disorders
(“functional overlay”) [27e29]. They usually manifest on the same
or contiguous body parts [28], but usually with different phe-
nomenology [27] (e.g. case 26: writer’s cramp and paroxysmal
psychogenic dystonic-choreoathetoid movements of the right arm;
video segment F1-2).Table 3
Red ﬂags for suspecting a psychogenic paroxysmal movement disorder.
Adult age of onset
Paroxysmal tremor as predominant clinical feature
High phenomenological variability between episodes
Precipitation of attack or increase in symptoms severity during examination
Atypical and variable duration of attacks
Presence of multiple atypical triggers
Altered level of responsiveness
Presence of odd precipitating factors
Presence of unusual relieving maneuvers
Additional psychogenic physical signs and/or medically unexplained somatic
symptoms
Atypical response to medication4.3. Attack duration
Attack durations are well deﬁned for primary PxD (Table 2). For
example a typical PKD attack lasts less then a minute in the vast
majority of cases [4,11,30]; PED attacks usually occur for 15min [12]
and PNKD episodes typically last a few hours [5]. The attack
duration of the psychogenic cases presented here was incongruent
with these classic forms. In particular, only three cases (cases 18, 20,
23) had recurring attacks for brief periods of time (<5 min), raising
the possibility of classic PKD. However, the phenomenology of the
attacks in these cases is incongruent with known PKD pre-
sentations and proposed diagnostic criteria (Table 2) [4]. Further-
more, not only attack duration, but also their very high intra- and
inter-individual variability (from seconds to hours or days) as re-
ported here and previously [25], should prompt considering PPMD
over primary PxD. Of note, secondary causes of PxD, can also pre-
sent with great between-subject variability of attack duration (e.g.
PNKD-like attacks lasting for seconds in one individual or 10e15
days in another) [17]. However, high within-subject variability does
not commonly occur in these conditions [17], as in the presented
cases here (e.g. case 15), and moreover, symptomatic causes have
been excluded in these patients.
4.4. Triggers
Primary forms of PxD have typical triggers (Table 2); classic PKD
is induced by sudden movement [4,30], PED by prolonged exercise
[3,12] and PNKD usually by coffee, alcohol and emotional stress [5].
The triggers in psychogenic caseswere atypical (e.g. video segments
A and B) and numerous for themajority of patients. (supplementary
Table 1). Even in cases where triggers similar to those seen in PNKD
were present (e.g. increased stress or alcohol intake; Table 2), the
clinical phenomenology of attacks remained incongruent.
4.5. Associated features
Precipitating factors and stressors were commonly reported in
our cases and involved physical and/or emotional distress. In
addition, three cases (11.5%) had additional rare episodes with al-
terations in responsiveness during some attacks. Further four cases
(15.3%) reported rare attack variations with “collapsing” events.
Interictal and ictal EEG recordings were respectively available in 5
and 4 of the aforementioned cases and were normal, prompting the
diagnosis of psychogenic non-epileptic seizures. Of note, even
though seizures are associated features of PKD and PED
[3,7,10,12,13], they occur independent to the attacks and have
classic epileptic characteristics.
Of the 11 patients with alleviating strategies, odd manoeuvres
(video segment C, F1 and F2), benzodiazepine intake, placebo
response to gabapentin, focussing on the affected body parts and
moving the non-affected contralateral limbs, exerting pressure on
affected body parts aswell as going to bedwere documented.While
patients with PxD have been reported to attempt controlling their
attack symptoms usually by exerting pressure on the affected limb
(“holding tight”) [1] or through benzodiazepine intake or sleep, the
remarkably variable and unusual strategies seen in our patients are
additional red ﬂags pointing towards the diagnosis of PPMD.
4.6. Treatment outcome
Themajority of the presented cases acknowledged the diagnosis
and wished to pursue further therapy, including physiotherapy and
cognitive behavioural treatment. This led to signiﬁcant improve-
ment of their symptoms. Three patients had botulinum toxin
treatments, two with persistent placebo responses.
C. Ganos et al. / Parkinsonism and Related Disorders 20 (2014) 41e46 45It is noteworthy that the number of PPMD patients with a sig-
niﬁcant clinical improvement is high and comparable to previous
reports [21,22,31]. In particular, Bressmann et al. reported clinical
remissions in ﬁve of 11 patients with PPMD upon different treat-
ments, and a dramatic improvement in an additional case with
hypnotherapy [22]. It therefore appears that PPMD might have a
better overall prognosis than other PMD [27,32,33]. However, as
systematic prospective data are not available, such comparisons do
not allow for unequivocal conclusions and suggest the need for
speciﬁc study in this area.
4.7. Study limitations
This studyhas several limitations. The retrospective design of our
data analysis is subject to potential errors, such as ascertainment
bias. Thus, the presented prevalence of PPMD among PMDmay not
be reﬂected in all clinical populations. However, the aim of the
current study was to provide a diagnostic pathway for clinicians
confronted with patients with paroxysmal movement disorders,
concentrating on clinical features suggesting a psychogenic cause.
We also acknowledge the difﬁculties of diagnosing PMD, in the
absence of biomarkers, solely based on available clinical criteria.
However,with theamountof informationavailable on thepresented
cases collected in our centre bymovement disorders specialistswith
long-standing experience in PMD (K.B., M.J.E.), including long
follow-up examinations for themajority,weare conﬁdent that these
patients fall within the borders of this diagnostic category. Although
not all attackswere observed during clinical examination, in none of
the presented cases did patients lose consciousness during their
paroxysmal episodes and all could accurately provide detailed de-
scriptions. Finally, comparisonswith primary PxDweremade based
on existing literature and not “head to head”with patients from our
centre. Given the rarity of the primary PxD, this allowed pooling
existing knowledge and using well-established diagnostic criteria
providing for accurate clinical inferences.
5. Conclusion
Although the phenotypic presentation of PPMD can be highly
diverse, after exclusion of secondary PxD conditions certain clinical
features help in distinguishing this condition from the primary
forms of PxD. These characteristics include an adult age of onset,
the presence of paroxysmal tremor, high within-subject phenom-
enological variability, marked increases in attack frequency and
severity during examination, highly variable attack duration,
numerous and unusual triggers, alteration of responsiveness during
attacks, odd precipitating factors and relieving manoeuvres,
medically unexplained somatic symptoms and atypical response to
medication. The communication of the diagnosis in an appropriate
manner was often useful therapeutically, and treatment with
physical and cognitive behavioural therapywas helpful in a number
of patients.
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